Posts

Showing posts with the label Lamotrigine

Phase II Metabolism

Image
Phase II Metabolism Excerpt from Cafer's Psychopharmacology, available soon on Amazon Phase II reactions typically involve conjugation of a substrate with glucuronic acid . This makes it water soluble and prepped for renal excretion. The responsible enzyme is U DP- g lucuronosyl t ransferase, abbreviated UGT , as in “U Got Tagged” with glucuronic acid.  Medications metabolized primarily by Phase II are relatively immune to drug interactions. Examples of clinically relevant Phase II interactions are those involving lamotrigine (Lamictal) as a substrate. Copyright 2020 CaferMed LLC

Lamotrigine (Lamictal)

Image
Excerpt from  Cafer's Mood Stabilizers and Antiepileptic Drugs ,  available on Amazon  ❖ Antiepileptic  ❖ Voltage-gated sodium  and calcium channel blocker  ❖ Glutamate ⇩  FDA approved for: ❖  Bipolar I maintenance ❖  Focal seizures ❖  Lennox-Gastaut syndrome  ❖  Bilateral tonic-clonic  seizures  Used off-label for: ❖  Bipolar II maintenance ❖  Major depressive  disorder ❖  Borderline personality  disorder ❖  Neuropathic pain ❖  Fibromyalgia ❖  PTSD ❖  Other seizure disorders  "Lamb ictal" - “Ictal” refers to a neurologic event such as a seizure.  Lamotrigine is the mood stabilizer of choice for maintenance of bipolar disorder . Lamotrigine has few health risks and few side effects . The most commonly reported side effects at high doses are dizziness and blurred vision . Lamotrigine does not cause weight gain and is generally non-sedating . No lab monitoring is...